Sirona Biochem Past Earnings Performance

Past criteria checks 0/6

Sirona Biochem has been growing earnings at an average annual rate of 15.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 6.6% per year.

Key information

15.7%

Earnings growth rate

20.5%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate6.6%
Return on equityn/a
Net Margin16,294.9%
Last Earnings Update31 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sirona Biochem makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:ZSB Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Jul 240-311
30 Apr 240-211
31 Jan 240-311
31 Oct 230-311
31 Jul 230-211
30 Apr 231-221
31 Jan 231-221
31 Oct 221-431
31 Jul 221-331
30 Apr 220-431
31 Jan 220-431
31 Oct 210-211
31 Jul 210-211
30 Apr 210-311
31 Jan 210-311
31 Oct 200-431
31 Jul 200-541
30 Apr 200-541
31 Jan 200-651
31 Oct 190-531
31 Jul 190-421
30 Apr 191-221
31 Jan 191-211
31 Oct 181-111
31 Jul 181-311
30 Apr 181-411
31 Jan 181-421
31 Oct 170-421
31 Jul 170-321
30 Apr 170-321
31 Jan 170-321
31 Oct 160-321
31 Jul 160-321
30 Apr 160-321
31 Jan 160-421
31 Oct 150-421
31 Jul 150-321
30 Apr 150-321
31 Jan 150-331
31 Oct 140-430
31 Jul 140-431
30 Apr 140-431
31 Jan 140-321

Quality Earnings: ZSB is currently unprofitable.

Growing Profit Margin: ZSB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ZSB is unprofitable, but has reduced losses over the past 5 years at a rate of 15.7% per year.

Accelerating Growth: Unable to compare ZSB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: ZSB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:43
End of Day Share Price 2024/12/20 00:00
Earnings2024/07/31
Annual Earnings2023/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sirona Biochem Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward AcklinFirst Berlin Equity Research GmbH
Jens HasselmeierFirst Berlin Equity Research GmbH